Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.40 |
| ▸ | SELE | P16581 | 3/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 6/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17844690 | 0.85 | DAO (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17844680 | 0.80 | HDAC1 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL31651689 | 0.77 | HDAC3 (0.38) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL24928227 | 0.69 | PTPN2 (0.39) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19964501 | 0.69 | LMNA (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30980400 | 0.69 | LMNA (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13295842 | 0.68 | CHRNA1 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17173223 | 0.68 | DAO (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL27623475 | 0.68 | NMT1 (0.40) | MAP2K1LMNA | |
| SCHEMBL31550028 | 0.67 | PTPN2 (0.38) | ICAM1SELEVCAM1PTPN2CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858347-B2 | Multicyclic compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858347-B2 | Multicyclic compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2019-01-17 | — | — | US | disclosed |
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2019-01-17 | — | — | US | disclosed |
| US-20180244660-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. | 2018-08-30 | — | — | US | disclosed |
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | Karyopharm Therapeutics Inc. | 2017-12-28 | — | — | US | disclosed |
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | Karyopharm Therapeutics Inc. | 2017-12-28 | — | — | US | disclosed |
| WO-2017117447-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017117447-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017031204-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017031204-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2016100515-A1 | CYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100515-A1 | CYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244660-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MALT1, BCL9, IKBKE | HDAC3 1528/4885HDAC4 1202/4885HDAC1 859/4885 |
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | MALT1, BCL9, BCL6 | HDAC3 900/4885HDAC4 386/4885HDAC1 244/4885 |
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | MALT1, BCL9, BCL6 | HDAC3 1462/4885HDAC4 943/4885HDAC1 1027/4885 |
| US-10858347-B2 | Multicyclic compounds and uses thereof | MALT1, BCL9, BCL6 | HDAC3 1462/4885HDAC4 943/4885HDAC1 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.